CTC Immune Checkpoint
Completed
- Conditions
- Prostate Cancer
- Registration Number
- NCT02456571
- Lead Sponsor
- Duke University
- Brief Summary
This pilot study will explore the prevalence of expression of four immune checkpoint biomarkers on circulating tumor cells (CTCs) from men with metastatic prostate cancer that are captured by EpCAM via the CellSearch method, and specifically defined as co expressing DAPI and cytokeratin, and lacking CD45 expression.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 38
Inclusion Criteria
Not provided
Exclusion Criteria
- History of intercurrent or past medical or psychiatric illness that would make participation in a blood drawing protocol difficult or not feasible at the discretion of the principal investigator or co-investigator(s).
- Treatment with an anthracycline (including mitoxantrone) within 1 week of CTC collection, as anthracyclines cause auto-fluorescence of cells.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in expression of four immune checkpoint biomarkers (PD-L1, PD-L2, B7-H3, and CTLA-4) on circulating tumor cells (CTCs). Baseline to 14 months (expected time of progression)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What immune checkpoint expression patterns on EpCAM-based CTCs correlate with immune evasion in metastatic prostate cancer?
How does PD-L1/CTLA-4/LAG-3/TIM-3 expression on CTCs compare to primary tumor samples in castration-resistant prostate cancer?
Which immune checkpoint biomarkers on CTCs predict response to PD-1/PD-L1 inhibitors in metastatic prostate cancer patients?
What adverse events are associated with immune checkpoint blockade in metastatic prostate cancer trials using CTC biomarkers?
How do EpCAM-based CTC isolation methods compare to CTC-iChip or microfluidic devices for immune checkpoint profiling in prostate cancer?
Trial Locations
- Locations (1)
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Duke University Medical Center🇺🇸Durham, North Carolina, United States